TEVA PHARMACEUTICAL FIN LLC's ticker is and the CUSIP is 88163VAE9. A total of 58 filers reported holding TEVA PHARMACEUTICAL FIN LLC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $740,000 | -2.4% | 8,000 | 0.0% | 0.09% | +31.3% |
Q4 2019 | $758,000 | +4.7% | 8,000 | 0.0% | 0.07% | -5.6% |
Q3 2019 | $724,000 | -1.1% | 8,000 | 0.0% | 0.07% | -4.1% |
Q2 2019 | $732,000 | -0.8% | 8,000 | 0.0% | 0.07% | -6.3% |
Q1 2019 | $738,000 | +2.2% | 8,000 | 0.0% | 0.08% | -14.1% |
Q4 2018 | $722,000 | -3.5% | 8,000 | 0.0% | 0.09% | +8.2% |
Q3 2018 | $748,000 | +0.8% | 8,000 | 0.0% | 0.08% | -7.6% |
Q2 2018 | $742,000 | +5.8% | 8,000 | 0.0% | 0.09% | 0.0% |
Q1 2018 | $701,000 | -0.1% | 8,000 | 0.0% | 0.09% | +7.0% |
Q4 2017 | $702,000 | -2.6% | 8,000 | 0.0% | 0.09% | -8.5% |
Q3 2017 | $721,000 | -16.0% | 8,000 | 0.0% | 0.09% | -15.3% |
Q2 2017 | $858,000 | -0.1% | 8,000 | 0.0% | 0.11% | -4.3% |
Q1 2017 | $859,000 | -1.9% | 8,000 | 0.0% | 0.12% | -10.1% |
Q4 2016 | $876,000 | -8.3% | 8,000 | 0.0% | 0.13% | -9.2% |
Q3 2016 | $955,000 | -4.8% | 8,000 | 0.0% | 0.14% | -13.4% |
Q2 2016 | $1,003,000 | -3.7% | 8,000 | 0.0% | 0.16% | -9.4% |
Q1 2016 | $1,041,000 | – | 8,000 | – | 0.18% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ZAZOVE ASSOCIATES LLC | 95,823,000 | $114,365,000 | 5.28% |
INCOME RESEARCH & MANAGEMENT | 12,056,000 | $14,384,000 | 2.34% |
AEGON USA Investment Management, LLC | 6,000,000 | $7,159,000 | 1.44% |
MACKAY SHIELDS LLC | 18,832,000 | $22,547,000 | 1.02% |
CSS LLC/IL | 14,850,000 | $17,728,000 | 0.86% |
SHENKMAN CAPITAL MANAGEMENT INC | 8,492,000 | $10,174,000 | 0.78% |
ADVENT CAPITAL MANAGEMENT /DE/ | 33,022,000 | $39,393,000 | 0.57% |
PALISADE CAPITAL MANAGEMENT, LP | 6,088,000 | $7,254,000 | 0.26% |
AXA S.A. | 34,000,000 | $40,566,000 | 0.18% |
SSI INVESTMENT MANAGEMENT LLC | 1,664,000 | $1,975,000 | 0.18% |